HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baly, D. L. Articles by Allison, D. E. Search for Related Content PubMed PubMed Citation Articles by Baly, D. L. Articles by Allison, D. E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CYTOCHALASIN B

A His₁₉ to Ala Mutant of Melanoma Growth-Stimulating Activity Is a Partial Antagonist of the CXCR2 Receptor

Genentech, Inc., South San Francisco, CA 94080

Melanoma growth stimulating activity (MGSA) and IL-8 are related chemokines that are potent chemoattractants and activators of neutrophils both in vitro and in vivo. Increasing evidence suggests that these molecules play an important role in inflammation; thus, antagonists of their action could be useful therapeutically as antiinflammatory agents. We have generated an MGSA mutant, H₁₉A, that shows a dissociation between receptor binding and biologic activity. The biologic activity of the H₁₉A mutant is between 133-fold and 282-fold less potent than that of wild-type MGSA measured by three independent assays of neutrophil function, i.e., elastase release chemotaxis and the up-regulation of CD18. In addition, pretreatment of cells with the H₁₉A mutant inhibited the ability of MGSA to induce elastase release and chemotaxis and to increase intracellular calcium. However, competition binding studies in cells transfected with the CXCR2 receptor and in neutrophils demonstrate that the receptor affinity of the H₁₉A mutant is only 13-fold less than that of wild-type MGSA. These studies suggest that the mutant MGSA is defective in activating signaling through the receptor and indicate that binding to the receptor is not sufficient to activate a biologic response. The dissociation between receptor binding and activation for this mutant suggests that it should be possible to design antagonists of MGSA that may be of clinical utility.

This article has been cited by other articles:

				L. Rajagopalan and K. Rajarathnam Ligand Selectivity and Affinity of Chemokine Receptor CXCR1: ROLE OF N-TERMINAL DOMAIN J. Biol. Chem., July 16, 2004; 279(29): 30000 - 30008. [Abstract] [Full Text] [PDF]